Catalog # 80-GLP1AU-CH01 Species Human, Mouse, Rat Regulatory Status Research Use Only. Not for Use in Diagnostic Procedures. Product Distribution Available Worldwide Range 0.23 - 314 pM (0.76 - 1036 pg/mL) Sensitivity < 0.06 pM (0.2 pg/mL) Sizes 96 Wells Sample Types EDTA Plasma, Serum Sample Size 25 µL Protocol Click here to view MSDS Click here to view
- Additional Information
Glucagon-like peptide-1 (GLP-1) is an extensively well-characterized incretin hormone which regulates both insulin and glucagon secretion. GLP-1 is a highly sought after therapeutic target due to its beneficial effects on glucose homeostasis, particularly through regulation of beta cell mass, function, and viability. GLP-1 is produced in intestinal L-cells in response to food and is well conserved across species. GLP-1 is derived from the cleavage of proglucagon to generate a 1-37 amino acid peptide. Fasting reduces circulating levels of GLP-1. GLP-1 has many physiological effects on the body. Diabetes and obesity scientists have been using two main GLP-1 research approaches: DPP-4 inhibition and GLP-1 analogs. DPP-4 can inactivate GLP-1 to its forms of GLP-1 (9-36) amide and GLP-1 (9-37) amide. By inhibiting DPP-4, scientists hope that GLP-1 can continue to influence insulin secretion and restore balance to energy homeostasis. The goal of developing GLP-1 analogs is to engineer a better GLP-1 molecule that has a longer half-life, thus providing longer influences over insulin secretion.
Currently available commercial ELISAs require large sample volumes or specialized instrumentation in order to achieve the desired sensitivity and to detect fasting levels of circulating GLP-1. Moreover, the variability within these assays, along with the lack of linearity and spike and recovery can, in many cases, lead to questions with regard to accuracy - even between different lots of the same kit. Keeping the aforementioned in mind, ALPCO has developed the STELLUX® Chemi Ultrasensitive Active GLP-1 ELISA (7-36) amide for the quantitative determination of GLP- 1 (7-36) amide in serum and plasma samples collected in the presence of DPP-IV inhibitor. Using a 25 μL sample size, this novel assay demonstrates excellent sensitivity of less than 0.25 pM, while specifically measuring GLP-1 (7-36) amide without any cross-reactivity to GLP-1 (1-36) amide, (1-37), (7-37), or (9-36). Specific detection of GLP-1 (7-36) amide is critical, as it is the major circulating biologically active fragment. Sequence conservation of GLP-1 across multiple species has enabled us to develop a single, low-volume assay which can discern fasted and fed levels in both human and rodent models. Most importantly, lack of matrix interference evaluated via dilutional linearity and spike and recovery studies ensures accuracy and precision.
Sensitivity: < 1 pM (3.3 pg/mL)
Range: 0.76 - 1355 pM (2.5 - 3452 pg/mL)
Sample Types: EDTA Plasma, Serum
Sample Size(s): 10 µL